Eli Lilly & Co. is targeting additional drug compounders and telehealth companies that make copycat versions of its weight ...
Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 ...
Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical ...
In a report released today, Steve Scala from TD Cowen maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...
The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...
Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment ...
Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lilly's (LLY) weight loss therapy tirzepatide & generic ...
Eli Lilly (NYSE:LLY) experienced a 6% increase in price over the last quarter, coinciding with several major developments.